Skip to main content
Top
Published in: Cancer Cell International 1/2017

Open Access 01-12-2017 | Primary Research

The human, F-actin-based cytoskeleton as a mutagen sensor

Authors: Nicolette M. Clark, Carlos A. Garcia Galindo, Vandan K. Patel, Michele L. Parry, Rebecca J. Stoll, John M. Yavorski, Elizabeth P. Pinkason, Edna M. Johnson, Chelsea M. Walker, Joseph Johnson, Wade J. Sexton, Domenico Coppola, George Blanck

Published in: Cancer Cell International | Issue 1/2017

Login to get access

Abstract

Background

Forty years ago the actin cytoskeleton was determined to be disrupted in fibroblasts from persons with DNA repair-defective, hereditary colon cancer, with no clear connection between the cytoskeleton and DNA repair defects at that time. Recently, the large number of sequenced genomes has indicated that mammalian mutagenesis has a large stochastic component. As a result, large coding regions are large mutagen targets. Cytoskeletal protein-related coding regions (CPCRs), including extra-cellular matrix proteins, are among the largest coding regions in the genome and are indeed very commonly mutated in cancer.

Methods

To determine whether mutagen sensitivity of the actin cytoskeleton could be assessed experimentally, we treated tissue culture cells with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and quantified overall cytoskeleton integrity with rhodamine-phalloidin stains for F-actin.

Results

The above approach indicated cytoskeletal degradation with increasing mutagen exposure, consistent with increased mutagenesis of CPCRs in TCGA, smoker samples, where overall mutation rates correlate with CPCR mutation rates (R2 = 0.8694; p < 0.00001). In addition, mutagen exposure correlated with a decreasing cell perimeter to area ratio, raising questions about potential decreasing, intracellular diffusion and concentrations of chemotherapy drugs, with increasing mutagenesis and decreasing cytoskeleton integrity.

Conclusion

Determination of cytoskeletal integrity may provide the opportunity to assess mutation burdens in nonclonal cell populations, such as in intact tissues, where DNA sequencing for heterogeneous mutation burdens can be challenging.
Appendix
Available only for authorised users
Literature
1.
go back to reference Parry ML, Ramsamooj M, Blanck G. Big genes are big mutagen targets: a connection to cancerous, spherical cells? Cancer Lett. 2015;356(2 Pt B):479–82.CrossRefPubMed Parry ML, Ramsamooj M, Blanck G. Big genes are big mutagen targets: a connection to cancerous, spherical cells? Cancer Lett. 2015;356(2 Pt B):479–82.CrossRefPubMed
2.
go back to reference Fawcett TJ, Parry ML, Blanck G. A novel approach to evaluating cancer driver gene mutation densities: cytoskeleton-related gene candidates. Cancer Genomics Proteomics. 2015;12(6):283–90.PubMed Fawcett TJ, Parry ML, Blanck G. A novel approach to evaluating cancer driver gene mutation densities: cytoskeleton-related gene candidates. Cancer Genomics Proteomics. 2015;12(6):283–90.PubMed
3.
go back to reference Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G, Lee JC, Henze J, Fletcher BS, Gu Z, et al. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014;46(6):601–6.CrossRefPubMedPubMedCentral Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G, Lee JC, Henze J, Fletcher BS, Gu Z, et al. Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014;46(6):601–6.CrossRefPubMedPubMedCentral
4.
go back to reference Fernandez K, Serinagaoglu Y, Hammond S, Martin LT, Martin PT. Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. Am J Pathol. 2010;176(1):416–34.CrossRefPubMedPubMedCentral Fernandez K, Serinagaoglu Y, Hammond S, Martin LT, Martin PT. Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts. Am J Pathol. 2010;176(1):416–34.CrossRefPubMedPubMedCentral
5.
go back to reference Blighe K, Kenny L, Patel N, Guttery DS, Page K, Gronau JH, Golshani C, Stebbing J, Coombes RC, Shaw JA. Whole genome sequence analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodes. PLoS ONE. 2014;9(12):e115346.CrossRefPubMedPubMedCentral Blighe K, Kenny L, Patel N, Guttery DS, Page K, Gronau JH, Golshani C, Stebbing J, Coombes RC, Shaw JA. Whole genome sequence analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodes. PLoS ONE. 2014;9(12):e115346.CrossRefPubMedPubMedCentral
6.
go back to reference Pollack R, Lo A, Steinberg B, Smith K, Shure H, Blanck G, Verderame M. SV40 and cellular gene expression in the maintenance of the tumorigenic syndrome. Cold Spring Harb Symp Quant Biol. 1980;44(Pt 1):681–8.CrossRefPubMed Pollack R, Lo A, Steinberg B, Smith K, Shure H, Blanck G, Verderame M. SV40 and cellular gene expression in the maintenance of the tumorigenic syndrome. Cold Spring Harb Symp Quant Biol. 1980;44(Pt 1):681–8.CrossRefPubMed
7.
go back to reference Verderame M, Alcorta D, Egnor M, Smith K, Pollack R. Cytoskeletal F-actin patterns quantitated with fluorescein isothiocyanate-phalloidin in normal and transformed cells. Proc Natl Acad Sci USA. 1980;77(11):6624–8.CrossRefPubMedPubMedCentral Verderame M, Alcorta D, Egnor M, Smith K, Pollack R. Cytoskeletal F-actin patterns quantitated with fluorescein isothiocyanate-phalloidin in normal and transformed cells. Proc Natl Acad Sci USA. 1980;77(11):6624–8.CrossRefPubMedPubMedCentral
8.
go back to reference Xu W, Mezencev R, Kim B, Wang L, McDonald J, Sulchek T. Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells. PLoS ONE. 2012;7(10):e46609.CrossRefPubMedPubMedCentral Xu W, Mezencev R, Kim B, Wang L, McDonald J, Sulchek T. Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells. PLoS ONE. 2012;7(10):e46609.CrossRefPubMedPubMedCentral
9.
go back to reference Kim TY, Vigil D, Der CJ, Juliano RL. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev. 2009;28(1–2):77–83.CrossRefPubMedPubMedCentral Kim TY, Vigil D, Der CJ, Juliano RL. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility. Cancer Metastasis Rev. 2009;28(1–2):77–83.CrossRefPubMedPubMedCentral
10.
go back to reference Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009;28(1–2):65–76.CrossRefPubMed Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009;28(1–2):65–76.CrossRefPubMed
11.
go back to reference Ben Amor M, Rauch F, Monti E, Antoniazzi F. Osteogenesis imperfecta. Pediatric Endocrinol Rev. 2013;10(Suppl 2):397–405. Ben Amor M, Rauch F, Monti E, Antoniazzi F. Osteogenesis imperfecta. Pediatric Endocrinol Rev. 2013;10(Suppl 2):397–405.
12.
go back to reference Hinson JT, Chopra A, Nafissi N, Polacheck WJ, Benson CC, Swist S, Gorham J, Yang L, Schafer S, Sheng CC, et al. HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. 2015;349(6251):982–6.CrossRefPubMedPubMedCentral Hinson JT, Chopra A, Nafissi N, Polacheck WJ, Benson CC, Swist S, Gorham J, Yang L, Schafer S, Sheng CC, et al. HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. 2015;349(6251):982–6.CrossRefPubMedPubMedCentral
13.
go back to reference Blanck G. Letter to the editor: giant proteins and cancer chemotherapy cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015;309(4):H718.CrossRefPubMed Blanck G. Letter to the editor: giant proteins and cancer chemotherapy cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015;309(4):H718.CrossRefPubMed
14.
go back to reference Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, Nagarajan U, Boss JM, Blanck G. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ. 2001;12(6):327–35.PubMed Goodwin BL, Xi H, Tejiram R, Eason DD, Ghosh N, Wright KL, Nagarajan U, Boss JM, Blanck G. Varying functions of specific major histocompatibility class II transactivator promoter III and IV elements in melanoma cell lines. Cell Growth Differ. 2001;12(6):327–35.PubMed
15.
go back to reference Dey N, Chattopadhyay DJ, Chatterjee IB. Molecular mechanisms of cigarette smoke-induced proliferation of lung cells and prevention by vitamin C. J Oncol. 2011;2011:561862.CrossRefPubMedPubMedCentral Dey N, Chattopadhyay DJ, Chatterjee IB. Molecular mechanisms of cigarette smoke-induced proliferation of lung cells and prevention by vitamin C. J Oncol. 2011;2011:561862.CrossRefPubMedPubMedCentral
16.
go back to reference McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303.CrossRefPubMedPubMedCentral McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9):1297–303.CrossRefPubMedPubMedCentral
18.
go back to reference DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491–8.CrossRefPubMedPubMedCentral DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43(5):491–8.CrossRefPubMedPubMedCentral
19.
go back to reference Cronin K, Escobar H, Szekeres K, Reyes-Vargas E, Rockwood AL, Lloyd MC, Delgado JC, Blanck G. Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Hum Vacc Immunother. 2013;9(4):784–9.CrossRef Cronin K, Escobar H, Szekeres K, Reyes-Vargas E, Rockwood AL, Lloyd MC, Delgado JC, Blanck G. Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Hum Vacc Immunother. 2013;9(4):784–9.CrossRef
20.
go back to reference Parry ML, Blanck G. Flat cells come full sphere: are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens? Hum Vacc Immunother. 2016;12(1):120–3.CrossRef Parry ML, Blanck G. Flat cells come full sphere: are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens? Hum Vacc Immunother. 2016;12(1):120–3.CrossRef
21.
go back to reference Gill TR, Samy MD, Butler SN, Mauro JA, Sexton WJ, Blanck G. Detection of productively rearranged TcR-alpha V-J Sequences in TCGA Exome Files: implications for tumor immunoscoring and recovery of antitumor T-cells. Cancer Inform. 2016;15:23–8.CrossRefPubMedPubMedCentral Gill TR, Samy MD, Butler SN, Mauro JA, Sexton WJ, Blanck G. Detection of productively rearranged TcR-alpha V-J Sequences in TCGA Exome Files: implications for tumor immunoscoring and recovery of antitumor T-cells. Cancer Inform. 2016;15:23–8.CrossRefPubMedPubMedCentral
22.
go back to reference Samim M, Prent N, Dicenzo D, Stewart B, Barzda V. Second harmonic generation polarization properties of myofilaments. J Biomed Opt. 2014;19(5):056005.CrossRefPubMed Samim M, Prent N, Dicenzo D, Stewart B, Barzda V. Second harmonic generation polarization properties of myofilaments. J Biomed Opt. 2014;19(5):056005.CrossRefPubMed
23.
go back to reference Zipfel WR, Williams RM, Christie R, Nikitin AY, Hyman BT, Webb WW. Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation. Proc Natl Acad Sci USA. 2003;100(12):7075–80.CrossRefPubMedPubMedCentral Zipfel WR, Williams RM, Christie R, Nikitin AY, Hyman BT, Webb WW. Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation. Proc Natl Acad Sci USA. 2003;100(12):7075–80.CrossRefPubMedPubMedCentral
24.
go back to reference Kopelovich L, Conlon S, Pollack R. Defective organization of actin in cultured skin fibroblasts from patients with inherited adenocarcinoma. Proc Natl Acad Sci USA. 1977;74(7):3019–22.CrossRefPubMedPubMedCentral Kopelovich L, Conlon S, Pollack R. Defective organization of actin in cultured skin fibroblasts from patients with inherited adenocarcinoma. Proc Natl Acad Sci USA. 1977;74(7):3019–22.CrossRefPubMedPubMedCentral
25.
go back to reference Parry ML, Blanck G. Flat cells come full sphere: are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens? Hum Vacc Immunother. 2015;12:120–3.CrossRef Parry ML, Blanck G. Flat cells come full sphere: are mutant cytoskeletal-related proteins oncoprotein-monsters or useful immunogens? Hum Vacc Immunother. 2015;12:120–3.CrossRef
Metadata
Title
The human, F-actin-based cytoskeleton as a mutagen sensor
Authors
Nicolette M. Clark
Carlos A. Garcia Galindo
Vandan K. Patel
Michele L. Parry
Rebecca J. Stoll
John M. Yavorski
Elizabeth P. Pinkason
Edna M. Johnson
Chelsea M. Walker
Joseph Johnson
Wade J. Sexton
Domenico Coppola
George Blanck
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2017
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-017-0488-5

Other articles of this Issue 1/2017

Cancer Cell International 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine